Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.045
-0.075 (-2.40%)
At close: Nov 20, 2024, 4:00 PM
3.190
+0.145 (4.76%)
After-hours: Nov 20, 2024, 6:27 PM EST
Anixa Biosciences Employees
As of October 31, 2023, Anixa Biosciences had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,472,200
Market Cap
97.99M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Akoya Biosciences | 330 |
Adagene | 174 |
Quantum-Si incorporated | 159 |
Assembly Biosciences | 65 |
InflaRx | 62 |
INmune Bio | 17 |
Monopar Therapeutics | 10 |
Telomir Pharmaceuticals | 9 |
ANIX News
- 2 days ago - Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 12 days ago - Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PRNewsWire
- 14 days ago - Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PRNewsWire
- 20 days ago - Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024 - PRNewsWire
- 23 days ago - Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PRNewsWire
- 5 weeks ago - Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 6 weeks ago - Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development - PRNewsWire
- 7 weeks ago - Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial - PRNewsWire